{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:24:59Z","timestamp":1792106699061,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.fjurol.2025.102921","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T18:28:42Z","timestamp":1750530522000},"page":"102921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predicting recurrence and progression in NMIBC: A multi-event and temporal analysis approach"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9055-3204","authenticated-orcid":false,"given":"Hugo","family":"Brouzes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Ourfali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Fassi-Fehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0790-1640","authenticated-orcid":false,"given":"Melanie","family":"Benoit-Janin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Maillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0152-8021","authenticated-orcid":false,"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2025.102921_bib0140","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0150","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study","volume":"163","author":"Lamm Donald","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0155","doi-asserted-by":"crossref","first-page":"F272","DOI":"10.1016\/j.fpurol.2024.07.209","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019AFU\u2013actualisation 2024-2026\u00a0: tumeurs de la vessie n\u2019infiltrant pas le muscle (TVNIM)","volume":"34","author":"Roumigui\u00e9","year":"2024","journal-title":"Prog En Urol FMC"},{"key":"10.1016\/j.fjurol.2025.102921_bib0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euf.2021.03.016","article-title":"Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence","volume":"8","author":"Laukhtina","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2025.102921_bib0165","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fjurol.2025.102921_bib0170","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0175","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","article-title":"Bacillus Calmette-Gu\u00e9rin therapy alters the progression of superficial bladder cancer","volume":"6","author":"Herr","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0180","first-page":"108e1","article-title":"BCG-refractory vs. BCG-relapsing non\u2013muscle-invasive bladder cancer: a prospective cohort outcomes study","volume":"33","author":"Herr","year":"2015","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.fjurol.2025.102921_bib0185","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/00365599.2011.599335","article-title":"Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Gu\u00e9rin immunotherapy on the outcome","volume":"45","author":"Zieger","year":"2011","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0190","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance Bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0195","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0200","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: implications for Clinical Trial Design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0205","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2016.02.031","article-title":"Papillary recurrence of bladder cancer at first evaluation after induction bacillus Calmette-Gu\u00e9rin Therapy: implication for clinical trial design","volume":"70","author":"Mmeje","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0210","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC Trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0215","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non\u2013muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0220","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.euo.2018.08.013","article-title":"Using grade of recurrent tumor to guide further therapy while on Bacillus Calmette-Guerin: low-grade recurrences are not benign","volume":"2","author":"Li","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0225","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0230","doi-asserted-by":"crossref","first-page":"E284","DOI":"10.1111\/j.1464-410X.2010.09980.x","article-title":"Early vs delayed radical cystectomy for \u2018high-risk\u2019 carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival: early vs delayed radical cystectomy","volume":"108","author":"J\u00e4ger","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2025.102921_bib0235","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","article-title":"Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)","volume":"27","author":"Hautmann","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000488200","article-title":"Diagnostic accuracy of F-18 FDG PET\/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis","volume":"95","author":"Ha","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.fjurol.2025.102921_bib0245","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/bju.14366","article-title":"Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis","volume":"122","author":"Gandhi","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2025.102921_bib0250","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00345-020-03474-8","article-title":"Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions","volume":"39","author":"Pfail","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0255","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/cancers16101843","article-title":"Treatment modalities for non-muscle invasive bladder cancer: an updated review","volume":"16","author":"McNall","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.fjurol.2025.102921_bib0260","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MOU.0000000000000882","article-title":"Artificial intelligence in bladder cancer prognosis: a pathway for personalized medicine","volume":"31","author":"Pinar","year":"2021","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.fjurol.2025.102921_bib0265","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41746-024-01088-7","article-title":"Predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: a systematic review using APPRAISE-AI","volume":"7","author":"Kwong","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.fjurol.2025.102921_bib0270","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.eururo.2024.08.004","article-title":"Re: predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: a systematic review using APPRAISE-AI","volume":"87","author":"Colombel","year":"2025","journal-title":"Eur Urol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025000683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025000683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T03:57:27Z","timestamp":1759636647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393025000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2950393025000683"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102921","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting recurrence and progression in NMIBC: A multi-event and temporal analysis approach","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102921"}}